Oncology and Hematology - Global Oncology Academy

289-304 of 651

Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Project Oncology®
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Ryan Quigley; David F. McDermott, MD
- Ryan Quigley
- David F. McDermott, MD
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Project Oncology®
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Jorge Nieva, MD
- Jorge Nieva, MD
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
Project Oncology®
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
Investigating the Impact of Exercise on Cancer Immunotherapy Outcomes
Investigating the Impact of Exercise on Cancer Immunotherapy Outcomes
Project Oncology®
Investigating the Impact of Exercise on Cancer Immunotherapy Outcomes
Samhitha Gundakaram, MBBS
- Samhitha Gundakaram, MBBS
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Project Oncology®
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Jorge Nieva, MD
- Jorge Nieva, MD
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
On the Frontlines of Prostate Cancer
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
William Oh, MD
- William Oh, MD
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
On the Frontlines of Prostate Cancer
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
Wayne Kuang, MD; William Oh, MD
- Wayne Kuang, MD
- William Oh, MD
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Project Oncology®
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Jorge Nieva, MD
- Jorge Nieva, MD
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Project Oncology®
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Project Oncology®
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Project Oncology®
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Jorge Nieva, MD
- Jorge Nieva, MD
Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Project Oncology®
Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
Project Oncology®
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
Vanessa Helou, MD
- Vanessa Helou, MD
Predicting Immunotherapy Outcomes in Head and Neck Cancer: The Role of Genetic Signatures
Predicting Immunotherapy Outcomes in Head and Neck Cancer: The Role of Genetic Signatures
Project Oncology®
Predicting Immunotherapy Outcomes in Head and Neck Cancer: The Role of Genetic Signatures
George Laliotis, MD, MPH, MHA
- George Laliotis, MD, MPH, MHA
Immune Checkpoint Inhibitors Show Promise in Patients with Oncogene Driver-Negative NSCLC Who Have Never Smoked
Immune Checkpoint Inhibitors Show Promise in Patients with Oncogene Driver-Negative NSCLC Who Have Never Smoked
Project Oncology®
Immune Checkpoint Inhibitors Show Promise in Patients with Oncogene Driver-Negative NSCLC Who Have Never Smoked
TIL^plus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
TIL^plus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
Project Oncology®
TIL^plus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC

19/11